Experience

Chemomab Therapeutics

• Israel
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• CMO and VP of Clinical Development

  • 2022 - Present

  New Jersey, United States Dr. Frankel is responsible for all drug development activities and medical affairs support.



Boehringer Ingelheim

• Germany
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Vice President, Clinical Development and Medical Affairs, Specialty Care

  • 2018 - 2022

  Ridgefield, CT Leading the medical affairs and late phase clinical development organization supporting therapeutic areas including oncology, immunology, pulmonary, and CNS. ● Develop, implement, guide and communicate BI’s Medical Affairs strategy and activities ● Work closely with the global organization to ensure alignment with the US priorities and implementation of global strategies ● Mentor and coach team



Novartis

• Switzerland
• Pharmaceutical Manufacturing
• 700 & Above Employee

• VP & Head of Immunology and Dermatology Medical Unit

  • 2016 - 2018

  East Hanover, NJ Leading the medical affairs and late phase clinical development organization supporting Cosentyx ® , Ilaris ® , and Zortress ® .



Sandoz

• Switzerland
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Executive Director, Medical Affairs

  • 2012 - 2016

  Princeton, NJ Shaping the biosimilar environment while leading a medical affairs infrastructure build out to accommodate biosimilar approvals. Supporting marketed product(s) including Omnitrope, Glatopa, Zarxio, and Erelzi..



Reata Pharmaceuticals

• United States
• Pharmaceutical Manufacturing
• 200 - 300 Employee

• Global Medical Director, Clinical Development

  • 2010 - 2012

  Dallas/Fort Worth Area Clinical lead in designing, planning and monitoring the Phase 3 study of bardoxolone methyl (an antioxidant inflammation modulator for patients with type 2 diabetes and chronic kidney disease) in support of the NDA • Coordinated four medical directors overseeing the 2000 patient study at 320 sites in 14 countries • Collaborated closely with external stakeholders (Steering Committee and National Leadership Committee) • Established the Data Monitoring Committee membership and charter;… Show more Clinical lead in designing, planning and monitoring the Phase 3 study of bardoxolone methyl (an antioxidant inflammation modulator for patients with type 2 diabetes and chronic kidney disease) in support of the NDA • Coordinated four medical directors overseeing the 2000 patient study at 320 sites in 14 countries • Collaborated closely with external stakeholders (Steering Committee and National Leadership Committee) • Established the Data Monitoring Committee membership and charter; and the Event Adjudication Committee membership and charter • Supported regulatory and clinical operations when answering outstanding IRB/EC/REB questions regarding trial conduct Show less



FibroGen

• United States
• Technology, Information and Internet
• 1 - 100 Employee

• Medical Director, Clinical Development

  • 2009 - 2010

  San Francisco Bay Area Clinical lead for FG4592 (a novel HIF-PHI) oral small molecule for anemia in chronic kidney disease in Phase 1 and 2 development • Contributed to the clinical development plan, investigators brochure, annual report and clinical study reports • Served as medical monitor for Phase 2 trial in pre-dialysis CKD patients • Maintained a close cooperative relationship with contract research organizations performing Phase 1 studies • Interfaced with Data Monitoring Committee



Facet Biotech

• Biotechnology Research
• 1 - 100 Employee

• Medical Director, Clinical Development

  • 2005 - 2009

  San Francisco Bay Area Clinical lead for visilizumab (an anti-CD3 antibody) - managed multiple Phase 2 and Phase 3 international studies (150 sites in 18 countries) investigating efficacy and safety in inflammatory bowel disease • Interfaced with regulatory authorities in the US and rest of the world as appropriate. Liaised with the regulatory, preclinical, safety and commercial groups to ensure preparedness for regulatory interactions • Integrally involved in developing a publication strategy, augmenting key… Show more Clinical lead for visilizumab (an anti-CD3 antibody) - managed multiple Phase 2 and Phase 3 international studies (150 sites in 18 countries) investigating efficacy and safety in inflammatory bowel disease • Interfaced with regulatory authorities in the US and rest of the world as appropriate. Liaised with the regulatory, preclinical, safety and commercial groups to ensure preparedness for regulatory interactions • Integrally involved in developing a publication strategy, augmenting key thought leader relationships and building CME • Reviewed study documents including case report forms, investigator brochure and annual reports • Provided clinical insight to due diligence teams evaluating early and mid stage development opportunities considered by corporate business development Show less



Schering Plough

• Belgium
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Medical Science Liaison, Medical Affairs

  • 2002 - 2005

  San Francisco Bay Area Senior Oncology Regional Medical Science Specialist • Effectively managed 6 person MSL Oncology team (November 2004 – September 2005) with project management accountability. • Developed and implemented the medical affairs strategic development plan for 2005 while collaborating with sales, marketing, and research • Collaborated with research and marketing in soliciting and evaluationg investigator sponsored trials Primary Care Regional Medical Science Liaison • Achieved… Show more Senior Oncology Regional Medical Science Specialist • Effectively managed 6 person MSL Oncology team (November 2004 – September 2005) with project management accountability. • Developed and implemented the medical affairs strategic development plan for 2005 while collaborating with sales, marketing, and research • Collaborated with research and marketing in soliciting and evaluationg investigator sponsored trials Primary Care Regional Medical Science Liaison • Achieved formulary status at multiple insititutions via presentations to managed care and governmental affairs. • Spearheaded training for the medical science specialist team regarding Zetia • Educated the commercial team supporting the allergy and immunology franchise including Nasonex, Foradil, and Clarinex Show less